卡伊-辛-桑通过准DHFR介导的叶酸-线粒体轴来缓解阿尔茨海默病
Simai Shao1, Runru Zu1, Hao Lu2
1Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan province, China; Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao, Henan Province.
Journal of ethnopharmacology
|January 18, 2026
概括
凯-辛-桑颗粒 (KXSG) 通过通过二甲酸还原酶 (DHFR) 相关的叶酸代谢增强线粒体功能,改善记忆力并保护阿尔茨海默氏症模型中的脑细胞.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 线粒体生物学 线粒体生物学
背景情况:
- 凯辛桑 (KXS) 是一种传统的中国草药配方,已使用1000多年来治疗认知障碍和痴呆症.
- 阿尔茨海默病 (AD) 的特点是线粒体功能障碍和认知能力下降.
研究的目的:
- 研究KXS颗粒 (KXSG) 缓解AD中的线粒体功能障碍的机制.
- 为了确定KXSG是否参与二叶酸还原酶 (DHFR) 相关的叶酸代谢,以发挥其作用.
主要方法:
- 用APP/PS1转基因小鼠和过度表达APP的HT22细胞来建模AD.
- 进行了行为测试,神经病理评估和线粒体超结构检查.
- 蛋白质组学,网络药理学和用甲状腺酸盐抑制DHFR被用来识别和验证目标.
主要成果:
- 在小鼠中,KXSG治疗改善了记忆力,保存了神经元,并减少了粉样β负担.
- 蛋白质组分析揭示了KXSG对与叶酸代谢相关的线粒体蛋白质的影响,DHFR被确定为关键目标.
- KXSG减轻了细胞中的线粒体功能障碍,部分正常化了叶酸代谢和DHFR表达;DHFR抑制减少了KXSG的益处.
结论:
- 在AD模型中,KXSG通过DHFR相关的叶酸代谢促进线粒体功能.
- 这项研究提供了证据,证明叶酸与线粒体之间的联系是KXS神经保护作用的基础.
相关概念视频
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...